254 filings
8-K
MTNB
Matinas Biopharma Holdings Inc
5 Apr 24
Matinas BioPharma Announces Registered Direct Offering of $10 Million
7:00am
424B5
MTNB
Matinas Biopharma Holdings Inc
4 Apr 24
Prospectus supplement for primary offering
4:15pm
8-K
MTNB
Matinas Biopharma Holdings Inc
28 Mar 24
Regulation FD Disclosure
9:00am
8-K
MTNB
Matinas Biopharma Holdings Inc
27 Mar 24
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
4:22pm
10-K
2023 FY
MTNB
Matinas Biopharma Holdings Inc
Annual report
27 Mar 24
4:02pm
8-K
eoriv4sdqz
25 Mar 24
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
8:05am
8-K
eyljjfoq mx2p821f
22 Mar 24
Regulation FD Disclosure
9:20am
8-K
sagki
22 Mar 24
Other Events
6:35am
8-K
2cc6zd qf
26 Feb 24
Regulation FD Disclosure
8:05am
8-K
c88q2
20 Feb 24
Regulation FD Disclosure
7:35am
8-K
xd9h840wmlj2a1tpzyc
9 Jan 24
Regulation FD Disclosure
7:30am
8-K
l8rdunc9l8brjjoej
27 Dec 23
In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions
7:40am
8-K
u1dtuc
21 Dec 23
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
7:40am
8-K
3yku9w
20 Nov 23
Regulation FD Disclosure
7:30am
8-K
ds8gfbdj
9 Nov 23
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
5:25pm
8-K
yzn3g
8 Nov 23
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:06pm
8-K
x97ce79hqz
2 Nov 23
Submission of Matters to a Vote of Security Holders
5:20pm
8-K
ybkguqg 7u4baa5
22 Sep 23
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
5:25pm
8-K
a54jb
20 Sep 23
Regulation FD Disclosure
7:30am